The recent death of George Floyd has set off a broad discussion around racism and the different forms of inequality people of color experience in the U.S. ...

Pfizer is tackling menopause in a new podcast series featuring honest conversations with women experiencing it. Called “Menopause: Unmuted,” the show is hosted ...

Unhappy with the price and availability of Gilead’s remdesivir—the only drug with FDA clearance to treat COVID-19—dozens of state attorney generals have called for t...

Finding patients with rare diseases is difficult enough, but even more so when diagnostic testing is needed to identify candidates. And the pandemic may be...

In stark contrast to many drugmakers registering second-quarter declines, Regeneron pulled off a 24% revenue increase on the strength of Eylea and Dupixent sale...

If Pfizer wants targeted lung cancer med Lorbrena to be a true follow-up to Xalkori, it has to get the product cleared in previously untreated ALK-positive patients....

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as Axel Hoos, the company’s SVP ...

AstraZeneca has shaken up the lucrative heart failure market with diabetes med Farxiga after a major approval earlier this year. But in kidney disease, another block...

With COVID-19 straining international relations over the supply of needed generic medicines, the U.S. has scrambled to pump up domestic production of those key drugs...

As companies worldwide grapple with sales challenges from the COVID-19 pandemic, Amgen is getting a boost from its newly acquired immunology blockbuster Otezla. Th...